Mammalian Cells Deploy Carbon-Sulfur Bond Cleavage to Generate Cysteine When Disulfide Reductase Systems Fail

The nine-year study began with 2014 observations that double-knockout mice remained viable despite theoretical lethality. Schmidt's team crossed single-reductase liver-specific lines and confirmed no residual disulfide reductase activity. Collaboration with Peter Nagy's group at the Hungarian National Institute of Oncology used mass spectrometry and isotopic tracing to map the backup route, showing direct scission of the cystine C-S bond yields free cysteine under electrophilic stress.

This pathway likely evolved as a toxin-defense mechanism and intersects with ferroptosis regulation. Cancer cells frequently depend on cysteine for glutathione synthesis; tumors under nutrient stress may exploit the backup route to evade therapies such as system xc- inhibitors or glutathione-depleting agents. Prior literature on erastin-induced ferroptosis (Dixon 2012, Cell) and cysteine metabolism (Jiang 2021, Nature Reviews Cancer) did not account for this redundancy, explaining why some predicted synthetic-lethal strategies underperformed.

Next steps require CRISPR validation in human cancer lines and development of selective inhibitors against the unidentified enzyme catalyzing C-S cleavage. If the pathway proves druggable, combination regimens could sensitize therapy-resistant tumors within five years.